Calamos Advisors
MDGL icon

Calamos Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Calamos Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Sell
3,490
-3,076
-47% -$1.47M 0.01% 686
2025
Q4 		$3.82M Buy
6,566
+2,081
+46% +$1.06M 0.01% 561
2025
Q3 		$2.06M Buy
+4,485
New +$1.67M 0.01% 622
2024
Q3 		– Sell
-4,112
Closed -$1.15M – 977
2024
Q2 		$1.15M Buy
4,112
+499
+14% +$119K 0.01% 633
2024
Q1 		$965K Buy
+3,613
New +$851K ﹤0.01% 647

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Calamos Advisors's MDGL Position: Q1 2026 in Review

Calamos Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 47% in Q1 2026, selling an estimated $1.47M and leaving 3,490 shares worth $1.83M. The position accounts for 0.01% of the portfolio, ranked #686.

Calamos Advisors first reported a position in MDGL in Q1 2024 and has held it in 5 quarters since. The position peaked at $3.82M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Calamos Advisors held 3,490 shares of Madrigal Pharmaceuticals worth $1.83M as of Q1 2026.
  • Calamos Advisors sold 3,076 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.47M.
  • Madrigal Pharmaceuticals made up 0.01% of Calamos Advisors's portfolio in Q1 2026, its #686 holding.
  • Calamos Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • Calamos Advisors's Madrigal Pharmaceuticals position peaked at $3.82M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.